Advancing Scientific Research to Improve Outcomes in the ICU
Investigator initiated research helps advance new innovations in critical care
The intensive care unit (ICU) of a hospital is where patients with critical illnesses and injuries are treated. There are many unknowns when it comes to treating critically-ill patients, who have complex conditions and require close monitoring and specialized care.
Our technology and medicines are used extensively in the ICU, from our leading infusion systems with built-in drug library software to clinical nutrition therapies and advanced technology to treat organ failure. We are also the global leader in systems used to treat the most severe form of acute kidney injury (AKI), which happens when the kidneys fail suddenly.
Baxter’s support to increase knowledge around issues facing critical care is crucial. Thanks to the grants I’ve received from Baxter, I have been able to investigate multiple aspects of critical care, renal replacement therapy and fluid therapy, and conduct important trials that have informed practice.
Rinaldo Bellomo, M.D. PhD, Fellow of the College of the College of Intensive Care Medicine, Professor of Intensive Care Medicine, The University of Melbourne, Australia
We are working with scientists and physicians around the world to understand the ever-evolving challenges in the ICU. One of the ways we’re doing this is by funding scientific research in many aspects of critical care – including acute kidney injury and cardiovascular function, continuous renal replacement therapy (CRRT) effectiveness, septic shock, organ function, and fluid balance.
“Baxter’s support to increase knowledge around issues facing critical care is crucial. Thanks to the grants I’ve received from Baxter, I have been able to investigate multiple aspects of critical care, renal replacement therapy and fluid therapy, and conduct important trials that have informed practice,” said Rinaldo Bellomo, M.D, PhD, Fellow of the College of Intensive Care Medicine, Professor of Intensive Care Medicine, The University of Melbourne, Australia.
As a global leader in the ICU, we have a responsibility to increase understanding of clinical conditions and therapeutic options for critically ill patients. We provide unrestricted research grants to scientists from around the world to identify key issues and potential ways to solve them – working to ultimately improve patient outcomes.
Dr. Kai Harenski, Global Medical Lead of Baxter's Acute Therapies business
Our team assesses proposals from around the globe to award investigator initiated research (IIR) grants. In 2018, we provided grants for 11 new studies focused on some of the most pressing issues in AKI and the critical care space: sepsis, CRRT and extracorporeal (outside the body) organ support therapies. As these studies are often conducted over the course of multiple years, we currently have a record number – 26 in total – of ongoing research projects. These projects are taking place in the U.K., Japan, India, Spain, the U.S. and more. Findings from these projects will contribute to the community’s knowledge of complex conditions and our approach to continual improvements through innovation.
“As a global leader in the ICU, we have a responsibility to increase understanding of clinical conditions and therapeutic options for critically ill patients,” said Kai Harenski, Global Medical Lead of Baxter’s Acute Therapies business. “We provide unrestricted research grants to scientists from around the world to identify key issues and potential ways to solve them – working to ultimately improve patient outcomes.”
Learn about Baxter’s leadership in critical care here.
